Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAZHT0)

Drug Name

TA-8995 Drug Info

Synonyms

Obicetrapib; UNII-8O74K609HN; 8O74K609HN; 866399-87-3; Obicetrapib [INN]; CHEMBL3785197; SCHEMBL17002081; AMG-899; DEZ-001; Obicetrapib (AMG-899 TA-8995); AKOS032954130; HY-18778; 4-((2-(((3,5-Bis(trifluoromethyl)phenyl)methyl)((2R,4S)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic acid; 1(2H)-Quinolinecarboxylic acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-,

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Phase 2	[1]
Hyperlipidaemia	5C80	Phase 2	[2]

Cross-matching ID

PubChem CID: 11498596
CAS Number: CAS 866399-87-3
TTD Drug ID: DMAZHT0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cholesteryl ester transfer protein (CETP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Evacetrapib	DMCDZ15	Cardiovascular disease	BA00-BE2Z	Phase 3	[4]
Dalcetrapib	DMKNCVM	Acute coronary syndrome	BA41	Phase 3	[5]
Anacetrapib	DMP2BFG	Arteriosclerosis	BD40	Phase 3	[6]
JTT-302	DMGLVBI	Lipid metabolism disorder	5C52.Z	Phase 2	[4]
DRL-17822	DMGD3XT	Arteriosclerosis	BD40	Phase 2	[4]
BAY-60-5521	DMXIDWE	Arteriosclerosis	BD40	Phase 1	[7]
Torcetrapib	DMDHYM7	Hyperlipidaemia	5C80	Discontinued in Phase 2	[8]
CETi-1	DMUG5OB	Arteriosclerosis	BD40	Discontinued in Phase 2	[9]
CP-800569	DMZ0YU7	Arteriosclerosis	BD40	Discontinued in Phase 1	[10]
R7232	DMETAP8	Dyslipidemia	5C80-5C81	Discontinued in Phase 1	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cholesteryl ester transfer protein (CETP)	TTFQAYR	CETP_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01970215) TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP). U.S. National Institutes of Health.
3	Amgen To Acquire Privately-Held Dezima Pharma
4	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
5	Clinical pipeline report, company report or official report of Roche (2009).
6	Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6.
7	Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8.
8	Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91.
9	CETi-1. AVANT. Curr Opin Investig Drugs. 2004 Mar;5(3):334-8.
10	Pfizer. Product Development Pipeline. March 31 2009.